Group 1 - The company, Zhenbao Island, announced a forecast for 2025 indicating a net profit loss of between 1.012 billion to 1.173 billion yuan, marking its first annual loss since its listing, primarily due to delayed procurement of traditional Chinese medicine and healthcare cost control, leading to a 53% year-on-year revenue decline and a 93% drop in gross profit [1] - Revenue has continuously declined from a peak of 4.219 billion yuan in 2022, with only 919 million yuan reported in the first three quarters of 2025, representing a 54.73% year-on-year decrease, while the net profit excluding non-recurring items has turned negative multiple times since 2022, indicating weakened core profitability [1] - The company's investment in innovative drug research and development is progressing slowly, making it difficult to support performance in the short term [1] Group 2 - The stock price of Zhenbao Island has experienced a continuous decline over the past seven days, with a total drop of 3.91%, closing at 8.12 yuan on February 12, down 1.81% for the day, and showing a net outflow of 11.388 million yuan in principal funds on the same day, with retail investors accounting for 36% [2] - Technical analysis indicates that the stock is in a bearish trend, with the moving average system showing a bearish arrangement, a resistance level at 9.33 yuan, and a support level at 7.96 yuan, underperforming compared to the pharmaceutical and biological sector and the broader market [2] Group 3 - On February 6, 2026, the controlling shareholder, Chuangda Group, announced a reduction in its shareholding from 56.98% to 55.86% due to the conversion of exchangeable bonds, although control has not changed [3] - As of February 10, Chuangda Group has pledged 80.48% of its shares, with an additional 1.17 million shares pledged to secure the exchangeable bond guarantee [3] - On February 6, the Ministry of Industry and Information Technology and other departments released the "High-Quality Development Plan for Traditional Chinese Medicine Industry (2026-2030)," emphasizing the upgrade of the entire industry chain, which aligns with Zhenbao Island's layout, but the short-term impact on performance is limited [3]

来源：市场资讯 有投资者在互动平台向昆药集团提问："公司公告说，中成药集采实际执行进度不及预期。请问中成药 集采在临床落地执行完成，2026年上半年能全部到位吗？" 声明：市场有风险，投资需谨慎。本文为AI基于第三方数据生成，仅供参考，不构成个人投资建议。 针对上述提问，昆药集团回应称："尊敬的投资者，您好。2025年2月，全国中成药集采（首批扩围接 续）中选结果正式公布，湖北省医保局于2025年4月公布全国中成药集采中选品种供应清单（含中选的 报价代表品和非代表品），公司三七血塞通系列产品全剂型顺利中选。湖北、江西两省自2025年4月30 日起官宣执行中选结果，其余多数省份陆续于2025年5-11月期间开始执行，目前全国所有省市均已发文 执行集采中选结果。对于集采中选的三七血塞通系列产品，公司积极把握医疗集采入围契机，提升产品 在各级医疗机构的覆盖；同时深耕动销、提升纯销、拓新商销，多维度发力寻求增量。面对集采执行进 度不均衡和医疗机构对接相应滞后、竞品增加及价格竞争加剧等不利因素的影响，公司积极调整渠道策 略，加快拓展商销渠道和中小连锁、基层医疗机构覆盖，为整体销量的恢复奠定基础。感谢您的关 注。" ...

Core Viewpoint - The traditional Chinese medicine company Zhenbaodao Pharmaceutical is expected to report a net loss of between 1.012 billion and 1.173 billion yuan for the fiscal year 2025, marking its first annual loss since its listing in 2015, nearly erasing the total net profit from the previous three years [1][10] Financial Performance - The company's revenue peaked at 4.219 billion yuan in 2022 but plummeted by 25.5% to 3.144 billion yuan in 2023, with a further decline of 13.84% to 2.707 billion yuan in 2024, falling below 2018 levels. In the first three quarters of 2025, revenue dropped by 54.73% to only 919 million yuan, indicating a trend towards a historical low for the year [2][11] - The net profit, excluding non-recurring gains and losses, turned negative for the first time in 2022, with a loss of 280 million yuan. Although the loss narrowed to 31.84 million yuan in 2023, the downward trend continued, with an expected loss of between 1.073 billion and 1.234 billion yuan in 2025 [4][13] Asset Structure and Risks - The company faces significant asset structure risks, with accounts receivable reaching 3.111 billion yuan by the end of September 2025, while revenue for the same period was only 919 million yuan, resulting in a ratio of accounts receivable to revenue of 338.52%. This ratio has been on the rise in recent years [4][13] - Inventory levels surged from 1.005 billion yuan in Q3 2023 to 1.521 billion yuan in Q3 2025, reflecting a more than 50% year-on-year increase, indicating severe sales obstacles and inventory accumulation issues [4][13] Operational Efficiency - The company's operational efficiency has deteriorated, with inventory turnover days and accounts receivable turnover days reaching historical highs of 692.31 days and 919.37 days, respectively, more than doubling compared to the previous year [5][14] Impairment Losses - Zhenbaodao plans to recognize approximately 395 million yuan in credit impairment losses and about 266 million yuan in asset impairment losses, with these combined losses exceeding 660 million yuan, significantly impacting annual performance [7][16] Business Challenges - Core products have been included in the national centralized procurement of traditional Chinese medicine, coupled with increased pressure from national medical insurance cost control, leading to significant price reductions. The anticipated volume increase through price reductions has not materialized, resulting in a decline in both volume and price [7][16] Research and Development - Despite attempts to explore new growth avenues, the company has significantly reduced R&D investments, with R&D expenses dropping by 52.64% to 37.99 million yuan in 2024, accounting for only 2.60% of revenue, far below industry leaders [8][17] - The company announced plans to invest over 400 million yuan in building an R&D platform for innovative drugs, but actual investment progress has been slow, with only 92.17 million yuan spent by mid-2025, representing 26.26% of the planned investment [8][17] Dividend Policy and Governance Issues - Zhenbaodao has maintained a rigid cash dividend policy, distributing a total of 1.302 billion yuan since its listing, despite deteriorating fundamentals. In 2023 and 2024, the company distributed 188 million yuan and 141 million yuan, respectively [9][18] - The concentrated ownership structure raises concerns, as the largest beneficiary of dividends is the controlling shareholder, with a high pledge ratio of 81% for the controlling shareholder's equity, increasing financial risks [9][18] - Governance issues were highlighted by a lack of proper procedures in a significant 425 million yuan subsidiary equity transfer, exposing internal control deficiencies [10][19] Conclusion - Zhenbaodao Pharmaceutical is facing severe challenges due to industry changes, internal governance issues, and actions by major shareholders, necessitating a balance between short-term returns and long-term development to restore fundamentals and rebuild market trust [10][19]

| 序号 | 申报企业 | 药品代码 | 通用名 | 商品名 | 剂型 | 規格 | 转换比 | 包装材质 | 包裝 单位 生产企业名称 | 分包装企 业名称 | 药品上市许可 持有人 | A/B组 | 备注 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 75 | 广州白云山屋群 (药业)股份有限 公司 | ZA10DAA009401 0300423 | 安神补脑液 | 无 | 合剂 | 每支装10ml(含 维生素B15mg) | 12 | 玻璃瓶 | 广州白云山星群 盒 (药业)股份有限公 日 | | 广州白云山星群(药 业)股份有限公司 | | | | | | | | | | 1 | | | | | | | | | | | | | | | | | | | | | | | 据了解，浙江第六批集采合计纳入45个品种，化药33个，中成药12个，严格遵循"技术评审+价格评审"双轨制，将临床疗效、质量可靠性、安全性等核心 指标置于评审首位。为保障临床用药需求与供应稳定性，评审还设置A ...

Core Viewpoint - Kunming Pharmaceutical Group Co., Ltd. is undergoing a critical phase of transformation amid complex external environments, leading to a projected revenue of 6.577 billion yuan and a net profit of 350 million yuan for 2025, with a decline in sales scale and gross margin compared to the previous year [1] Group 1: Business Performance - In 2025, the company faces operational pressure due to multiple factors, including accelerated integration in the pharmaceutical retail industry and normalized medical insurance cost control policies [2] - The company acknowledges the challenges it faces and is actively adjusting its business strategies to seek sustainable development solutions [2] Group 2: Industry Context - The traditional Chinese medicine procurement is moving towards normalization and scale, with increased pricing and market share control for existing products, indicating a shift towards a more standardized and intensive development phase in the industry [2] - Industry experts believe that while short-term pressures may arise from procurement policies, long-term benefits will help the company establish a sustainable competitive advantage in a more transparent market environment [3] Group 3: Strategic Focus - The company is focusing on the silver economy, which is supported by national strategies and dual policy and demand dividends, aiming to become a leader in the silver health industry [4] - The company has built a diversified product matrix covering chronic disease management and emotional health, leveraging its established market foundation in the Sanqi industry chain and cardiovascular treatment products [4] - The company is committed to deepening its existing advantages in the silver health sector and steadily expanding its market presence [5]

Core Viewpoint - The traditional Chinese medicine company Heilongjiang Zhenbaodao Pharmaceutical Co., Ltd. has reported its first loss in ten years, highlighting the challenges faced by the industry during a significant transformation period [2][4]. Financial Performance - Zhenbaodao expects a net profit loss of approximately -1.173 billion to -1.012 billion yuan for the fiscal year 2025, marking a dramatic shift from profit to loss compared to the previous year [2]. - The company's net profit has decreased by 330.94% to 367.68% year-on-year, setting a record for the worst performance in its history [2]. - In the first half of 2025, the company's revenue plummeted by 57.04% to 713 million yuan, with a net loss of 78.29 million yuan, a 119.9% decline year-on-year [6]. Market Challenges - The decline in performance is attributed to several factors, including lower-than-expected sales of core products, price reductions, and significant credit impairment losses of approximately 395 million yuan [4][6]. - The company’s core products, which account for over 70% of its revenue, have been affected by national procurement policies and ongoing healthcare cost controls [4][5]. Strategic Issues - Zhenbaodao's heavy reliance on traditional products and slow innovation has led to strategic difficulties, forcing the company to drastically cut sales and R&D expenses to maintain cash flow [4][6]. - The company’s R&D expenditure has significantly decreased by 52.64% to 37.99 million yuan, representing only 2.60% of its revenue, which is well below the industry average [7]. Governance Concerns - The company faced criticism from the Shanghai Stock Exchange for a 425 million yuan equity transfer that bypassed required approval processes, raising governance concerns [8][9]. - Despite the financial downturn, Zhenbaodao continued to distribute dividends totaling 141 million yuan in 2024, leading to market skepticism regarding the management's priorities and potential wealth transfer to major shareholders [9]. Industry Outlook - The significant loss signals a broader trend where traditional Chinese medicine companies relying on single products and inefficient operations may struggle to survive as procurement practices become more standardized [10]. - Zhenbaodao is attempting to adjust its strategy by focusing on innovation in traditional Chinese medicine, biopharmaceuticals, and chemical drugs, while also restructuring its marketing approach [10].

Core Viewpoint - Chengdu Huasheng Technology Group Co., Ltd. is expected to report a net loss of 270 million to 330 million yuan in 2025, marking a decline of 3935.75% to 4832.59% year-on-year, indicating a severe financial crisis for the company [2][3]. Financial Performance - The company's revenue has shown significant volatility, with operating income dropping from 873 million yuan in 2022 to 864 million yuan in 2024, and a projected revenue of only 457 million yuan in the first three quarters of 2025, a year-on-year decrease of 31.02% [5][6]. - The net profit attributable to shareholders has plummeted from 41.22 million yuan in 2022 to a loss of 6.69 million yuan in 2024, marking the first loss since 2016 [5][6]. - As of the end of Q3 2025, the company's total assets were 1.862 billion yuan, down 17.2% from the previous year, and net assets attributable to shareholders were 932 million yuan, down 9.1% [6]. Operational Challenges - The core product, Sanqi Tongshu Capsule, has seen its price halved due to national centralized procurement, leading to a drastic reduction in revenue and profit contributions [4][5]. - The company has faced a series of structural challenges, including a significant reduction in inventory by downstream customers to mitigate price volatility risks, further compressing short-term revenue [4][5]. - Strategic adjustments, such as scaling down the construction steel structure business, have negatively impacted overall performance in the short term [5]. Market Reaction - Following the earnings forecast, the company's stock price has come under pressure, reflecting investor concerns about its future development [7]. - The company’s liquidity is under strain, with cash reserves of only 149 million yuan against current liabilities of 800 million yuan, indicating potential operational difficulties [7]. Strategic Responses - The company is attempting to address its financial challenges through a strategic reduction of non-core assets and optimizing resource allocation [8]. - Huasheng Technology has initiated a plan to raise up to 450 million yuan through a private placement to alleviate liquidity pressures [7][10]. Industry Context - The challenges faced by Huasheng Technology are indicative of broader issues within the traditional Chinese medicine industry, particularly in light of deepening reforms in the pharmaceutical system and the increasing prevalence of centralized procurement policies [9]. - The Chinese traditional medicine market is projected to exceed 580 billion yuan by 2030, driven by an aging population, which presents both challenges and opportunities for companies in the sector [10].

Investment Rating - The report gives a "Buy" rating for the company, with a target price of 23.37 CNY based on a PE valuation of 57 times for 2026 [3][6]. Core Insights - The company is expected to benefit from a dual-driven strategy of traditional Chinese medicine (TCM) and chemical drugs, with a gradual clearance of the impact from centralized procurement on TCM business. The innovative drug pipeline is entering a harvest phase, with projected net profits for 2025-2027 being 290 million, 350 million, and 410 million CNY respectively, corresponding to EPS of 0.34, 0.41, and 0.48 CNY [3][9]. Summary by Sections 1. Dual-Driven Strategy of TCM and Chemical Drugs - The company has a rich product layout and maintains stable performance, with a focus on TCM and high-end generic drugs. The revenue from TCM has historically contributed over 50% of total revenue, while the share of chemical drugs has increased from 24% in 2016 to 36% in 2024 [13][16]. - The company launched an employee stock ownership plan in 2024 to incentivize core personnel, focusing on performance assessment and innovative drug development [23][24]. 2. Innovative Product Data and Growth Potential - The company has several innovative products entering commercialization or late-stage clinical trials. Notably, RAY1225, a dual-target drug for obesity and diabetes, has shown superior efficacy in clinical trials compared to existing treatments [27][29]. - ZSP1601, a first-in-class drug for NASH, is currently in IIb phase clinical trials and has demonstrated promising results in reducing liver inflammation markers [45][49]. 3. Core TCM Products and Market Recovery - The company's core TCM product, Compound Thrombus Tong Capsule, has maintained a leading market share in the ophthalmic TCM sector. As the impact of centralized procurement diminishes, sales are expected to stabilize and recover [9][18]. - The Brain Thrombus Capsule, another key product, has shown stable clinical demand and is projected to continue its steady growth [9][18].

随着2026年7月1日《中药注册管理专门规定》第七十五条落地最后窗口期的临近，"大批中成药将退出市场"的相关话题近日引发广泛关注。真实情况是 否如此？家中常备中成药还安全吗？一起来看。 问：大批中成药真的将退出市场吗？ 答：不会出现"大批集中退市"的情形，而是不合规品种有序退出。此次政策针对的是药品再注册环节，即批准文号到期后需重新申请的中成药，并非直 接淘汰现有在售产品。 另一方面，第四批中成药集采已启动，首次纳入OTC产品和部分独家品种，参考前三批集采，中成药平均降幅可达40％以上，将进一步拉低常用药价 格。对于疗效确切、数据齐全的优质中成药，虽企业合规成本有所上升，但监管层明确"优质优价"导向，价格会保持稳定，不会盲目上涨，群众用药负 担整体将有所减轻。 答：已上市产品可正常使用。此次政策核心是补齐说明书安全信息短板，而非否定中成药的临床价值。 首先，政策针对的是药品再注册环节，即药品批准文号到期后重新申请时需符合新标准，目前家中已有的库存、市面上正在销售的中成药，均为合法合 规产品，不受直接影响。 其次，一些常用中成药龙头企业已提前布局，投入资金补充安全评价数据，可顺利完成说明书修订。专家提醒，后续部 ...

Summary of Sanli Pharmaceutical Conference Call Company Overview - **Company**: Sanli Pharmaceutical - **Core Products**: Kaohoujian series, particularly the pediatric version with over 80% coverage in secondary hospitals [2][4] Industry Insights - **Market Focus**: The company aims to enhance coverage in grassroots medical institutions, which could significantly boost sales if products are included in the essential drug list [2][4] - **OTC Business Development**: Sanli is focusing on developing its OTC business, segmented into respiratory and elderly care lines to meet market demands [2][6] Financial Projections - **2026 Revenue Forecast**: Expected total revenue of approximately 1.9 to 2 billion CNY, with contributions from: - Respiratory line: 1.2 to 1.3 billion CNY - Supplement line: 400 to 500 million CNY - Other product lines: 100 to 200 million CNY - **2025 Performance Outlook**: Anticipated revenue of 1.6 to 1.7 billion CNY due to low incidence of respiratory diseases and inventory pressure [3][21] Product Pipeline and R&D - **Essential Drug List Candidates**: Four products are potential candidates for the essential drug list, with the pediatric Kaohoujian having the highest probability of inclusion [4][13] - **Innovation Strategy**: The company has shifted focus from classic formulas to innovative traditional Chinese medicine, collaborating with research institutions on multiple projects expected to yield results in six to eight years [11][24] Market Strategy - **Sales Channel Expansion**: Sanli has transitioned from prescription sales to a multi-channel sales approach, including partnerships with top national chains and an emphasis on O2O (online-to-offline) retail strategies [6][18] - **Grassroots Market Potential**: The company aims to increase its market share in grassroots settings, currently at 5% to 8%, with a target of 20% to 30% for successful products [15] Competitive Landscape - **Impact of Drug List Adjustments**: Inclusion in the essential drug list could significantly enhance market penetration and prescription volumes for key products [12][14] - **Response to Price Reductions**: The company does not view price reductions from centralized procurement as detrimental, as it can reduce sales expenses to maintain profit margins [17] Operational Readiness - **Capacity and Distribution**: Preparations for the new essential drug list have been ongoing since 2018, focusing on channel development and distribution team enhancements [16] - **Integration of Acquisitions**: The integration of acquired companies is nearly complete, with a unified sales strategy across the OTC business [22] Challenges and Risks - **Inventory Management**: The company has faced inventory pressures due to low disease incidence, impacting financial performance in 2025 [20] - **Market Competition**: The company acknowledges the competitive landscape in the orthopedic and gynecological sectors, which are not yet significant revenue contributors [7] Conclusion Sanli Pharmaceutical is strategically positioned to enhance its market presence through innovative product development, expansion into grassroots healthcare, and a robust OTC strategy. The potential inclusion of key products in the essential drug list could further drive growth, despite current challenges related to inventory and market competition.